From a clinical perspective, most patients with MBL are identified because of lymphocytosis and have B-cell counts between 3 and 5 Â 10 9 /l. Although such individuals with 'high count' MBL progress to require treatment for CLL at a rate of B1% per year (a rate much lower than patients with CLL), 8 whether their survival differs from that of age-and sex-matched individuals is unknown. Conceptually, patients with the precursor state to malignancy should have a risk of death similar to those without the precursor state unless they progress to develop malignancy.
To determine the impact of 'high count' MBL on survival, we compared the survival of an established cohort of patients with clinically recognized CLL-like MBL with the age-and sexmatched population. In addition, to explore whether the current B-cell threshold used to segregate MBL from CLL optimally classifies risk of death, we also evaluated the survival of patients with newly diagnosed Rai 0 CLL and a B-cell count between 5 and 10 Â 10 9 /l or newly diagnosed Rai 0 CLL patients with a B-cell count 410 Â 10 9 /l to the age-and sex-matched population. As previously described, 8 hematopathology records were used to identify a cohort of 1815 patients with a clonal B-cell population of CLL phenotype 6 detected by flow cytometric analysis at Mayo Clinic between January 2000 and December 2006. After elimination of patients with more advanced stage (Rai I-IV) CLL, previously treated CLL, or an established diagnosis of CLL/MBL X1 year before the flow cytometric study, 631 unique CLL patients were identified. A B-cell count could be determined using flow cytometric immunophenotyping analysis in combination with a complete blood count with differential cell count for 619 (98%) of these patients. 8 On the basis of current criteria, patients with a total B-cell count o5 Â 10 9 /l were classified as having MBL, whereas patients with a total B-cell count X5 Â 10 9 /l were classified as Rai 0 CLL. 2, 6 To evaluate the clinical associations with different lymphocyte thresholds, individuals with Rai 0 CLL were sub-classified based on whether their absolute B-cell count was between 5 and 10 Â 10 9 /l or 410 Â 10 9 /l. Data on survival were obtained from clinical records and the US Social Security Death Index, and was therefore complete on all patients. Expected survival was calculated using the Cohort (Hakulinen) method with estimates based on the overall Minnesota population, which is demographically similar to patients seen at Mayo Clinic.
10,11 P-values p0.05 were considered significant. A detailed description of the demographic characteristics of this cohort have been previously reported. 8 The median followup of patients with MBL in this series is now 59 months. A summary of patient characteristics along with updated information on absolute lymphocyte count progression, development of lymphadenopathy, treatment status and vital status are shown in Table 1 . Updated treatment-free survival is shown in the Supplementary Figure. During the first 5 years of followup, the rate of progression requiring treatment was B1%/year for MBL, 3%/year for Rai 0 CLL with a B-cell count between 5 and 10 Â 10 9 /l, and 5%/year for patients with Rai 0 CLL and a B-cell count410 Â 10 9 /l. We next evaluated the overall survival of patients with high count MBL relative to the age-and sex-matched population. Although it appeared slightly lower, the survival of patients with clinically recognized MBL was not statistically different than that of age-and sex-matched individuals (P ¼ 0.14; Figure 1a ). In contrast, the survival of patients with newly diagnosed Rai 0 CLL and a B-cell count between 5 and 10 Â 10 9 /l (P ¼ 0.02; Figure 1b ) and newly diagnosed Rai 0 CLL with a B-cell count 410 Â 10 9 /l (Po0.001; Figure 1c ) were both significantly shorter than that of the age-and sex-matched population.
Although these data are consistent with the designation of clinically recognized MBL as a premalignant condition and support the current B-cell threshold used to distinguish between MBL and CLL, a more nuanced story emerged when individuals with clinical recognized MBL were stratified by the CD38 status of the B-cell clone. Although the survival of MBL cases with a CD38À clone (n ¼ 231; 79%) was not different than that of ageand sex-matched individuals (P ¼ 0.22), the survival for those with a CD38 þ clone (n ¼ 60; 21%) was substantially shorter than that of the age-and sex-matched population (P ¼ 0.0003; Figure 1d ). Owing to an insufficient number of patients with ZAP-70, IGHV gene mutation status or fluorescence in situ For patients with repeat lymphocyte count at least 6 months after baseline or who demonstrated a doubling in o6 months.
Letters to the Editor hybridization analysis, we could not accurately evaluate the correlation of other established prognostic variables with survival. The data on CD38 suggest that prognostic parameters used to stratify risk among patients with CLL may identify which individuals with MBL have a clinical outcome different than that of the age/sex matched population. It should also be emphasized that these results do not suggest that individuals with clinically recognized MBL who have more aggressive biological features (such as being CD38 positive) will necessarily do badly as much as they suggest that the 80-90% of individuals with clinically recognized MBL who have favorable biological characteristics are likely to do very well and can be reassured.
Several limitations of our analysis should be noted. Overall survival rather than disease-specific survival was used as the primary end point. This is the most objective outcome, the one of greatest interest to patients (for example, 'will this diagnosis shorten my life?'), and accounts for the possibility that individuals with MBL may be at excess risk for death independent of whether they progress to develop CLL or another lymphoproliferative disorder as has been observed in patients with monoclonal gammopathy of undetermined significance. 12 Nonetheless, information on cause specific survival would also be of interest. Reliable data on cause specific survival is very difficult to assign in retrospective cohort studies and is not available for the current cohort. Nonetheless, the strong association between survival and CD38 status among individuals with MBL who were CD38 positive suggests that the observed increased risk for death was largely related to CLL specific events. Prospective studies in this area will be important.
Collectively, these data provide powerful additional clinical evidence in support of the designation of clinically recognized MBL as a premalignant condition. However, in addition to absolute B-cell count, the results suggest that biological characteristics of the B-cell clone influence survival in patients with clinically recognized MBL. Additional studies with larger samples and longer follow-up are needed to determine whether such characteristics should be considered when classifying individuals with B-cell clones o5 Â 10 9 /l as having a premalignant or malignant condition. 
